Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Clinuvel Pharmaceuticals Ltd (CUV.AX)

Clinuvel Pharmaceuticals Ltd (CUV.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Clinuvel Pharmaceuticals Ltd 535 Bourke Street Level 22 Melbourne VIC 3000 AUS

https://www.clinuvel.com P: +61 396604900 F: +61 396604909

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Key Statistics

Overview:

Market Capitalization, $K 613,955
Shares Outstanding, K 50,201
% of Institutional Shareholders 10.87%
Annual Net Income, $ 36,173 K
3-Year Return -54.09%
5-Year Return -43.69%
5-Year Revenue Growth 23.88%
5-Year Earnings Growth 16.82%
5-Year Dividend Growth 14.87%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm 0.72
EPS Growth vs. Prev Year 0.03%
Annual Dividend & Yield (Paid) 0.05 (0.41%)
Annual Dividend & Yield (Fwd) 0.05 (0.41%)
Most Recent Dividend 0.050 on 09/04/25
Next Ex-Dividends Date 09/04/25
Dividend Payable Date 09/19/25
Dividend Payout Ratio 6.96%
Most Recent Split 1-10 on 11/12/10

CUV.AX Ratios

Ratio
Price/Earnings ttm 17.03
Price/Earnings forward 16.37
Return-on-Equity % 16.30%
Return-on-Assets % 14.39%
Profit Margin % 38.07%
Debt/Equity 0.00
Price/Sales 6.48
Price/Book 2.55
Book Value/Share 4.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar